Pharming Group (NASDAQ:PHAR - Get Free Report) shares traded down 6.8% during trading on Monday . The stock traded as low as $10.53 and last traded at $10.53. 206 shares were traded during trading, a decline of 92% from the average session volume of 2,465 shares. The stock had previously closed at $11.30.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 14th.
Check Out Our Latest Analysis on Pharming Group
Pharming Group Price Performance
The company's fifty day moving average is $11.17 and its two-hundred day moving average is $11.54. The firm has a market capitalization of $685.19 million, a price-to-earnings ratio of -72.92 and a beta of 0.16. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.62.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. The business had revenue of $81.20 million during the quarter, compared to analyst estimates of $71.83 million. Equities research analysts anticipate that Pharming Group will post -0.02 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC bought a new position in Pharming Group (NASDAQ:PHAR - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 11,715 shares of the company's stock, valued at approximately $134,000. Institutional investors and hedge funds own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.
Featured Articles
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
